INNOVATE (NYSE:VATE) Posts Quarterly Earnings Results, Beats Estimates By $3.28 EPS

INNOVATE (NYSE:VATE) announced its quarterly earnings data on Thursday. The company reported $1.10 earnings per share for the quarter, beating the consensus estimate of ($2.18) by $3.28, FiscalAI reports. The company had revenue of $495.50 million during the quarter, compared to analyst estimates of $251.70 million.

Here are the key takeaways from INNOVATE’s conference call:

• INNOVATE reported third-quarter revenue of $495.5 million and adjusted EBITDA of $40.5 million, up from $347.1 million and $19.8 million a year earlier; net income attributable to common and participating preferred stockholders was $15.8 million. The improvement was driven primarily by infrastructure, especially DBM Global, whose results benefited from higher activity and project efficiencies.
• The company completed the sale of DBM Global after quarter-end, receiving approximately $413 million in cash and retaining an ownership interest in IES Holdings; it also sold a controlling interest in broadcasting while keeping a 25% stake and an option to increase it. INNOVATE said it used DBM sale proceeds to repay its corporate credit line and redeem $325 million of senior secured notes, reducing principal indebtedness from $583.3 million to $238.3 million.
• MediBeacon reported progress toward broader adoption of its TGFR System, reimbursement initiatives, and U.S. validation studies for a wireless sensor; it also secured orders for 600 monitors in China, with shipments planned from late 2026 through the second quarter of 2027. Management cautioned that conversion of commercial interest may take six to 12 months, and initial pharmaceutical clinical-trial use is anticipated in 2027.
• R2 cited worldwide demand of 3.1 million, but recognized only $1.2 million in quarterly revenue, and life sciences revenue overall fell 61.3% year over year to $1.2 million. R2 said manufacturing is expanding, with 116 systems carried into the fourth quarter representing roughly $1.9 million of potential future revenue, but converting demand into sales remains a key execution challenge.

INNOVATE Trading Down 8.2%

Shares of INNOVATE stock traded down $0.43 during midday trading on Thursday, hitting $4.84. 68,202 shares of the company traded hands, compared to its average volume of 60,522. INNOVATE has a 12 month low of $3.75 and a 12 month high of $21.30. The firm’s fifty day moving average price is $6.59 and its 200-day moving average price is $8.86.

Analysts Set New Price Targets

VATE has been the topic of a number of analyst reports. Wall Street Zen downgraded shares of INNOVATE from a “strong-buy” rating to a “buy” rating in a research note on Saturday, September 12th. Weiss Ratings restated a “sell (e+)” rating on shares of INNOVATE in a research report on Wednesday. One investment analyst has rated the stock with a Sell rating. According to data from MarketBeat, the company has an average rating of “Sell”.

INNOVATE Company Profile

INNOVATE Corp. (NYSE: VATE) is a diversified holding company focused primarily on infrastructure and life sciences businesses. Through its subsidiaries, the company operates businesses involved in structural steel fabrication, industrial construction, engineering and related infrastructure services, as well as the development and commercialization of medical technologies. Its infrastructure operations are centered on DBM Global, a provider of structural steel and related services for commercial, industrial, institutional and infrastructure projects.